Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung

Gene Therapy

Volumn 18, Issue 10, 2011, Pages 996-1005

  McLachlan, G ^a   Davidson, H ^b   Holder, E ^b   Davies, L A ^c   Pringle, I A ^c   Sumner Jones, S G ^c   Baker, A ^a   Tennant, P ^a   Gordon, C ^a   Vrettou, C ^a   Blundell, R ^d   Hyndman, L ^b   Stevenson, B ^b   Wilson, A ^b   Doherty, A ^b   Shaw, D J ^a   Coles, R L ^g   Painter, H ^c   Cheng, S H ^e   Scheule, R K ^e   Davies, J C ^f   Innes, J A ^b   Hyde, S C ^c   Griesenbach, U ^f   Alton, E W F W ^f   Boyd, A C ^b   Porteous, D J ^b   Gill, D R ^c   Collie, D D S ^a   more..

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e GENZYME CORPORATION   (United States)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g NONE

Author keywords

aerosol; cystic fibrosis; gene delivery; lung; non viral; sheep

Indexed keywords

CATIONIC LIPOSOME; COMPACTED DNA NANOPARTICLE; COMPLEMENTARY DNA; HAPTOGLOBIN; LIPOSOME; MACROGOL; NANOPARTICLE; POLYETHYLENEIMINE; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; EPITHELIUM CELL; GENE EXPRESSION; LUNG FIBROSIS; LUNG LAVAGE; LUNG PARENCHYMA; NEUTROPHILIA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; SHEEP;

ADMINISTRATION, INHALATION; ANIMALS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DNA, COMPLEMENTARY; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; LIPOSOMES; NANOPARTICLES; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; RNA, MESSENGER; SHEEP;

ANIMALIA; OVIS; OVIS ARIES;

EID: 80054087238     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.55     Document Type: Article

References (33)

1. Griesenbach U, Alton EWFW, UK Cystic Fibrosis Gene Therapy Co. Gene transfer to the lung: Lessons learned frommore than 2 decades of CF gene therapy. Adv Drug Deliv Rev 2009; 61: 128-139.
2. Hyde SC, Gill DR, Higgins CF, Trezise AEO, MacVinish LJ, Cuthbert AWet al. Correction of the ion-transport defect in cystic-fibrosis transgenic mice by gene-therapy. Nature 1993; 362: 250-255. (Pubitemid 23093631)
3. McLachlan G, Ho L-H, Davidson-Smith H, Samways J, Davidson H, Stevenson BJ et al. Laboratory and clinical studies in support of cystic fibrosis gene therapy using pCMVCFTR/DOTAP. Gene Ther 1996; 3: 1113-1123. (Pubitemid 27036115)
4. Alton EWFW, Middleton PG, Caplen NJ, Smith SN, Steel DM, Munkonge FM et al. Noninvasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nat Genet 1993; 5: 135-142. (Pubitemid 23293448)
5. Rogers CS, Hao Y, Rokhlina T, Samuel M, Stoltz DA, Li Y et al. Production of CFTR-null and CFTR-Delta F508 heterozygous pigs by adeno-associated virus-mediated gene targeting and somatic cell nuclear transfer. J Clin Invest 2008; 118: 1571-1577. (Pubitemid 351500450)
6. Sun X, Yan Z, Yi YL, Li ZY, Lei D, Rogers CS et al. Adeno-associated virus-targeted disruption of the CFTR gene in cloned ferrets. J Clin Invest 2008; 118: 1578-1583. (Pubitemid 351500451)
7. Stoltz DA, Meyerholz DK, Pezzulo AA, Ramachandran S, Rogan MP, Davis GJ et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med 2010; 2: 29ra31.
8. Emerson M, Renwick L, Tate S, Rhind S, Milne E, Painter HA et al. Transfection efficiency and toxicity following delivery of naked plasmid DNA and cationic lipid-DNA complexes to ovine lung segments. Mol Ther 2003; 8: 646-653. (Pubitemid 37321694)
9. McLachlan G, Baker A, Tennant P, Gordon C, Vrettou C, Renwick L et al. Optimizing aerosol gene delivery and expression in the ovine lung. Mol Ther 2007; 15: 348-354. (Pubitemid 46111885)
10. Davies LA, McLachlan G, Sumner-Jones SG, Ferguson D, Baker A, Tennant P et al. Enhanced lung gene expression after aerosol delivery of concentrated pDNA/PEI complexes. Mol Ther 2008; 16: 1283-1290. (Pubitemid 351866060)
11. Griesenbach U, Sumner-Jones SG, Holder E, Munkonge FM, Wodehouse T, Smith SN et al. Limitations of the murine nose in the development of non-viral airway gene transfer. Am J Respir Cell Mol Biol 2010; 43: 46-54.
12. Eastman SJ, Lukason MJ, Tousignant JD, Murray H, Lane MD, St George JA et al. A concentrated and stable aerosol formulation of cationic lipid:DNA complexes giving high-level gene expression in mouse lung. Hum Gene Ther 1997; 8: 765-773. (Pubitemid 27202063)
13. Alton EW, Stern M, Farley R, Jaffe A, Chadwick SL, Phillips J et al. Cationic lipidmediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 1999; 353: 947-954. (Pubitemid 29132602)
14. Ruiz FE, Clancy JP, Perricone MA, Bebok Z, Hong JS, Cheng SH et al. A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosis. Hum Gene Ther 2001; 12: 751-761. (Pubitemid 32692341)
15. Densmore CL, Orson FM, Xu B, Kinsey BM, Waldrep JC, Hua P et al. Aerosol delivery of robust polyethyleneimine-DNA complexes for gene therapy and genetic immunization. Mol Ther 2000; 1: 180-188.
16. Rudolph C, Ortiz A, Schillinger U, Jauernig J, Plank C, Rosenecker J. Methodological optimization of polyethylenimine (PEI)-based gene delivery to the lungs of mice via aerosol application. J Gene Med 2005; 7: 59-66.
17. Ziady AG, Gedeon CR, Miller T, Quan W, Payne JM, Hyatt SL et al. Transfection of airway epithelium by stable PEGylated poly-L-lysine DNA nanoparticles in vivo. Mol Ther 2003; 8: 936-947. (Pubitemid 38072306)
18. Ziady AG, Gedeon CR, Muhammad O, Stillwell V, Oette SM, Fink TL et al. Minimal toxicity of stabilized compacted DNA nanoparticles in the murine lung. Mol Ther 2003; 8: 948-956. (Pubitemid 38072307)
19. Konstan MW, Davis PB, Wagener JS, Hilliard KA, Stern RC, Milgram LJH et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum Gene Ther 2004; 15: 1255-1269. (Pubitemid 40052437)
20. Oette SM, Gedeon CR, Kowalczyk TH, Fink TL, Hyatt SL, Moen RC et al. Aerosols of compacted DNA nanoparticles retain structural integrity and biological activity. Mol Ther 2004; 9: S190.
21. Davidson H, McLachlan G, Wilson A, Boyd AC, Doherty A, MacGregor G et al. Human specific CFTR antibodies detect in vivo gene transfer to ovine airways. Am J Respir Cell Mol Biol 2006; 35: 72-83.
22. Gill DR, Smyth SE, Goddard CA, Pringle IA, Higgins CF, Colledge WH et al. Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1 alpha promoter. Gene Ther 2001; 8: 1539-1546. (Pubitemid 33061892)
23. Johnson LG, Olsen JC, Sarkadi B, Moore KL, Swanstrom R, Boucher RC. Efficiency of gene-transfer for restoration of normal airway epithelial function in cystic-fibrosis. Nat Genet 1992; 2: 21-25.
24. Farmen SL, Karp PH, Ng P, Palmer DJ, Koehler DR, Hu J et al. Gene transfer of CFTR to airway epithelia: low levels of expression are sufficient to correct Cl-transport and overexpression can generate basolateral CFTR. Am J Physio Lung Cell Mol Physio 2005; 289: L1123-L1130. (Pubitemid 41681347)
25. Mckone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 2003; 361: 1671-1676. (Pubitemid 36577438)
26. Dorin JR, Farley R, Webb S, Smith SN, Farini E, Delaney SJ et al. A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction. Gene Ther 1996; 3: 797-801. (Pubitemid 26326685)
27. Cunningham S, Meng QH, Klein N, McAnulty RJ, Hart SL. Evaluation of a porcine model for pulmonary gene transfer using a novel synthetic vector. J Gene Med 2002; 4: 438-446. (Pubitemid 40282549)
28. Yew NS, Wang KX, Przybylska M, Bagley RG, Stedman M, Marshall J et al. Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid:pDNA complexes. Hum Gene Ther 1999; 10: 223-234. (Pubitemid 29070636)
29. Chen X, Kube DM, Cooper MJ, Davis PB. Cell surface nucleolin serves as receptor for DNA nanoparticles composed of pegylated polylysine and DNA. Mol Ther 2008; 16: 333-342. (Pubitemid 351168043)
30. Chadwick SL, Kingston HD, Stern M, Cook RM, OConnor BJ, Lukasson M et al. Safety of a single aerosol administration of escalating doses of the cationic lipid GL-67/DOPE/DMPE-PEG formulation to the lungs of normal volunteers. Gene Ther 1997; 4: 937-942. (Pubitemid 27437719)
31. Hyde SC, Pringle IA, Abdullah S, Lawton AE, Davies LA, Varathalingam A et al. CpGfree plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 2008; 26: 549-551. (Pubitemid 351668040)
32. Rose AC, Goddard CA, Colledge WH, Cheng SH, Gill DR, Hyde SC. Optimisation of realtime quantitative RT-PCR for the evaluation of non-viral mediated gene transfer to the airways. Gene Ther 2002; 9: 1312-1320.
33. Coles R, Stoneham C, McLachlan G, Vrettou C, Gill D, Hyde SC et al. Quantifying nonviral gene transfer by real-time PCR: a cautionary tale. Hum Gene Ther 2009; 20: 1514.